ArticleFrontiers in medicine2026
Integrating active surveillance and HPV vaccination for high-risk CIN2: a strategy to reduce disease progression.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to identify risk factors associated with disease progression in women with cervical intraepithelial neoplasia grade 2 (CIN2) undergoing active surveillance and to evaluate the protective effect of human papillomavirus (HPV) vaccination administered after diagnosis. Methods: This single-center, retrospective cohort study included 510 women (mean age 30.15 ± 5.82 years, range 18-61) with histologically confirmed CIN2 who chose active surveillance between January 2012 and March 2021. Patient demographics, clinical characteristics, and HPV vaccination status were collected and analyzed. Primary and secondary outcomes were complete regression, persistence, and progression of disease (to CIN3, adenocarcinoma Results: Over a mean follow-up period of 37.0 months, 65.9% (336 of 510) of patients achieved complete regression, 10.8% (55 of 510) exhibited persistent CIN2, and 6.3% (32 of 510) experienced disease progression. A multivariate analysis identified HPV16 infection (OR 4.07, 95%CI 1.88-8.81) and having more than three pregnancies (OR 4.38, 95%CI 1.63-11.79) as independent risk factors for progression. Notably, HPV vaccination administered after CIN2 diagnosis was found to be an independent protective factor (OR 0.29, 95%CI 0.08-0.98). The Kaplan-Meier estimated 5-year progression rate was 72% (5 of 13 patients) in the high-risk subgroup (unvaccinated, HPV16-positive women with more than three pregnancies), compared with only 7.6% (27 of 497 patients) in the low-risk subgroup (vaccinated, HPV16-negative women with three or fewer pregnancies). Conclusion: Active surveillance is a safe and effective management strategy for the majority of women with CIN2. Risk stratification using HPV16 infection status and pregnancy history is crucial for personalized management. HPV vaccination after CIN2 diagnosis is strongly recommended, as it significantly reduces the risk of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.